BTS 54-505 hydrochloridePotent SNRI,sibutramine metabolite CAS# 84484-78-6 |
- ARL 67156 trisodium salt
Catalog No.:BCC7004
CAS No.:1021868-83-6
- ML-7 hydrochloride
Catalog No.:BCC1770
CAS No.:110448-33-4
- Sodium Orthovanadate
Catalog No.:BCC3856
CAS No.:13721-39-6
- Tipifarnib (Zarnestra)
Catalog No.:BCC2253
CAS No.:192185-72-1
- Ciclopirox ethanolamine
Catalog No.:BCC4372
CAS No.:41621-49-2
- Omecamtiv mecarbil
Catalog No.:BCC3710
CAS No.:873697-71-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 84484-78-6 | SDF | Download SDF |
PubChem ID | 134771 | Appearance | Powder |
Formula | C15H23Cl2N | M.Wt | 288.26 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in water and to 100 mM in DMSO | ||
Chemical Name | 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine;hydrochloride | ||
SMILES | CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N.Cl | ||
Standard InChIKey | KHRVYINTXCWNRF-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C15H22ClN.ClH/c1-11(2)10-14(17)15(8-3-9-15)12-4-6-13(16)7-5-12;/h4-7,11,14H,3,8-10,17H2,1-2H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potently active primary amine metabolite of sibutramine, exhibits a similar pharmacological profile to the parent compound. Inhibits serotonin and noradrenalin reuptake more potently than sibutramine in vitro. Reduces food intake in rodents following i.c.v. administration and increases energy expenditure via thermogenesis in vivo. |
BTS 54-505 hydrochloride Dilution Calculator
BTS 54-505 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4691 mL | 17.3455 mL | 34.6909 mL | 69.3818 mL | 86.7273 mL |
5 mM | 0.6938 mL | 3.4691 mL | 6.9382 mL | 13.8764 mL | 17.3455 mL |
10 mM | 0.3469 mL | 1.7345 mL | 3.4691 mL | 6.9382 mL | 8.6727 mL |
50 mM | 0.0694 mL | 0.3469 mL | 0.6938 mL | 1.3876 mL | 1.7345 mL |
100 mM | 0.0347 mL | 0.1735 mL | 0.3469 mL | 0.6938 mL | 0.8673 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: 0.066 μM for noradrenaline uptake; 5.1 μM for 5-HT uptake; 0.31 μM for dopamine uptake
Sibutramine HCl (BTS 54-524) is an inhibitor of the reuptake of monoamines with a pharmacological profile in rodents indicative of non-tricyclic putative antidepressant activity. BTS 54-505 is the primary amine metabolite of sibutramine.
In vitro: Simultaneous application of BTS 54-505 with 5-HT resulted in a prolongation of the recovery time from the 5-HT-mediated suppression of discharge activity. BTS 54-505 also prolonged the recovery time from a NA-mediated potentiation of firing. These effects on recovery time are attributed to the inhibition of uptake of both 5-HT and NA by BTS 54-505. The amplitude of the response to 5-HT or NA was unaffected by co-ejection of BTS 54-505 [1].
In vivo: The secondary (BTS 54-354) and primary (BTS 54-505) amine metabolites of sibutramine HCl exhibit similar in vivo pharmacological activity to the parent compound. Thus, each compound displays potent activity in acute behavioural models predictive of antidepressant effects and a comparable ability to inhibit the uptake of monoamines [2].
Clinical trial: Up to now, BTS 54-505 is still in the preclinical development stage.
Reference:
[1] Scott G, Luscombe GP, Mason R. The effects of BTS 54-505, a metabolite of sibutramine, on monoamine and excitatory amino acid-evoked responses in the rat dorsolateral geniculate nucleus in vivo. Br J Pharmacol. 1994 Jan;111(1):97-102.
[2] Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology. 1989 Feb;28(2):129-34.
- C-1
Catalog No.:BCC6687
CAS No.:84468-24-6
- threo-Guaiacylglycerol-beta-O-4'-dehydrodisinapyl ether
Catalog No.:BCN6928
CAS No.:844637-85-0
- β-CCB
Catalog No.:BCC6635
CAS No.:84454-35-3
- A-769662
Catalog No.:BCC2080
CAS No.:844499-71-4
- AT7519
Catalog No.:BCC2541
CAS No.:844442-38-2
- Fmoc-NH2
Catalog No.:BCC2803
CAS No.:84418-43-9
- 23-Hydroxybetulin
Catalog No.:BCN6463
CAS No.:84414-40-4
- alpha-Arbutin
Catalog No.:BCN8336
CAS No.:84380-01-8
- Bretazenil
Catalog No.:BCC7711
CAS No.:84379-13-5
- Neuromedin S (rat)
Catalog No.:BCC6055
CAS No.:843782-19-4
- Adoxosidic acid
Catalog No.:BCN7593
CAS No.:84375-46-2
- Mifepristone
Catalog No.:BCC4486
CAS No.:84371-65-3
- Sibutramine hydrochloride
Catalog No.:BCC5252
CAS No.:84485-00-7
- Varlitinib (ARRY334543)
Catalog No.:BCC3725
CAS No.:845272-21-1
- Sevelamer Carbonate
Catalog No.:BCC4717
CAS No.:845273-93-0
- ICI 162,846
Catalog No.:BCC6808
CAS No.:84545-30-2
- Bedaquiline fumarate
Catalog No.:BCC5245
CAS No.:845533-86-0
- MNI-caged-D-aspartate
Catalog No.:BCC5896
CAS No.:845555-94-4
- Bitopertin
Catalog No.:BCC1419
CAS No.:845614-11-1
- Bitopertin (R enantiomer)
Catalog No.:BCC1420
CAS No.:845614-12-2
- 4-Hydroxycephalotaxine
Catalog No.:BCN4386
CAS No.:84567-08-8
- PHA-767491
Catalog No.:BCC1858
CAS No.:845714-00-3
- Rocaglamide
Catalog No.:BCN4387
CAS No.:84573-16-0
- Cleomiscosin C
Catalog No.:BCN4388
CAS No.:84575-10-0
Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine.[Pubmed:12187403]
Int J Obes Relat Metab Disord. 2002 Sep;26(9):1245-53.
OBJECTIVE: To investigate the pharmacological mechanisms underlying the induction of thermogenesis by Metabolite 2 (M2; BTS 54 505), a major pharmacologically active metabolite of the anti-obesity drug, sibutramine. DESIGN: Adult female Wistar rats were treated with M2 or vehicle, with or without various monoamine receptor antagonists, prazosin, RS79948, metergoline, propranolol and (+)butaclamol. MEASUREMENTS: Colonic temperature and food intake at room temperature (21+/-1 degrees C), thermoregulatory behavioural response, operant responding for exogenous heat at -8 degrees C and oxygen consumption at thermoneutrality (29 degrees C). RESULTS: M2 (10 mg/kg, p.o.) significantly increased colonic temperature during the 4.5 h period following drug administration. This effect was abolished by the non-selective 5-HT receptor antagonist, metergoline (1 mg/kg, p.o.), and alpha(1)-adrenoceptor antagonist, prazosin (1 mg/kg, p.o.), measured at 1.5-2.5 h post-M2 administration, and was partially antagonized by each antagonist at 3.5-4.5 h. The non-selective beta-adrenoceptor antagonist, propranolol (1 mg/kg, p.o.), had no effect on the M2-induced increase in colonic temperature, whereas at 20 mg/kg (p.o.), propranolol partially inhibited the effect of M2 on colonic temperature. By contrast, the selective alpha(2)-adrenoceptor antagonist, RS79948 (1 mg/kg, p.o.), and the D2/D1 receptor antagonist, (+)butaclamol (200 micro g/kg, p.o.), did not alter the effect of M2 on colonic temperature. In the thermoregulatory study, M2 (10 mg/kg, i.p.)-treated rats required significantly less radiant heat at -8 degrees C to maintain body temperature, and this effect was not affected by the D2/D1 receptor antagonist (+)butaclamol (100 micro g/kg(-1), i.p.). The hypophagia induced by M2 (10 mg/kg) measured up to 24 h was partially antagonized by the alpha(1)-adrenoceptor antagonist, prazosin, whereas metergoline, RS79948, propranolol and (+)butaclamol had no effect on M2-induced hypophagia. CONCLUSION: It is concluded that 5-HT, alpha(1)- and beta(3)-adrenoceptors are involved in the induction of thermogenesis by M2, whereas the hypophagic effect is mainly mediated via alpha(1)-adrenoceptors. These findings are consistent with M2 increasing 5-HT and noradrenaline tone via potent reuptake inhibition which subsequently results in increased efferent sympathetic activity to brown adipose tissue (BAT).
In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.[Pubmed:9353373]
J Pharmacol Exp Ther. 1997 Nov;283(2):581-91.
Because monoamine reuptake inhibitors and releasing agents both increase extracellular neurotransmitter levels, establishing in vivo experimental criteria for their classification has been difficult. Using microdialysis in the hypothalamus of unanesthetized rats, we provide evidence that serotonin- (5-HT) selective and nonselective reuptake inhibitors can be distinguished from the 5-HT-releasing agent fenfluramine by four criteria: 1) Systemic fenfluramine produces a much greater increase in 5-HT than the reuptake inhibitors. 2) The 5-HT somatodendritic autoreceptor agonist, (+/-)-8-hydroxy-(dipropylamino)tetralin (8-OH-DPAT), attenuates the increase in 5-HT produced by reuptake inhibitors, but not by fenfluramine. 3) The large increase in 5-HT produced by infusion of reuptake inhibitors into the hypothalamus is attenuated by their systemic administration. However, systemic injection of fenfluramine during its local infusion does not attenuate this increase. 4) Reuptake inhibitor pretreatment attenuates fenfluramine-induced increases in 5-HT. According to these criteria, the in vivo effects of the novel antiobesity drug sibutramine are consistent with its characterization as a 5-HT reuptake inhibitor and not a 5-HT releaser. Thus, sibutramine produced increases in hypothalamic 5-HT similar in magnitude to the effects of the known reuptake inhibitors, and the increase was attenuated by 8-OH-DPAT. Also, sibutramine attenuated fenfluramine-induced 5-HT release. Systemic administration of sibutramine failed to attenuate the increase in 5-HT produced by its local infusion, suggesting that this criterion is not applicable to compounds with low affinity for the 5-HT transporter.
The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride.[Pubmed:2541365]
Neuropharmacology. 1989 Feb;28(2):129-34.
Sibutramine HCl is an inhibitor of the reuptake of monoamines with a pharmacological profile in rodents indicative of antidepressant activity. The secondary (BTS 54 354) and primary (BTS 54 505) amine metabolites of the tertiary amine sibutramine HCl exhibit similar in vivo pharmacological activity to the parent compound. Thus, each compound displays potent activity in acute behavioural models predictive of antidepressant effects and a comparable ability to inhibit the uptake of monoamines in vivo. In addition, BTS 54 354 and BTS 54 505 induce an equally rapid and potent down-regulation of cortical beta-adrenoceptors in the rat as sibutramine HCl. The secondary and primary amines are, however, considerably more active than sibutramine HCl as inhibitors of the uptake of noradrenaline, dopamine and 5-hydroxytryptamine in vitro. The potent inhibition of the reuptake of noradrenaline by the secondary and primary amine metabolites probably contributes to the rapid and potent down-regulation of beta-adrenoceptors in the rat, induced by the putative antidepressant sibutramine HCl.